Stereotaxis, Inc. Common Stock
STXSStereotaxis, Inc. is a medical technology company that specializes in the development and application of robotic systems for minimally invasive cardiac procedures. Founded in 2001, the company focuses on using innovative robotics and imaging technologies to improve the precision, safety, and outcomes of electrophysiology and cardiac surgery interventions. Its flagship product, the Niobe robotic magnetic navigation system, aids physicians in navigating catheters within the heart with enhanced accuracy.
Company News
Stereotaxis will release its Q3 2025 financial results on November 11, 2025, and host a conference call at 4:30 p.m. ET to discuss company results and developments.
Stereotaxis, a leader in surgical robotics, will release its Q1 2025 financial results on May 12, 2025 and host a conference call to discuss the company's performance and developments.
The global magnetic ablation catheters market is expected to grow significantly, reaching $1.1 billion by 2035, driven by advancements in technology and the rising prevalence of cardiovascular diseases. Key factors driving growth include the increasing adoption of minimally invasive procedures and continued investment in healthcare infrastructure...
The global medical robot market is set to witness significant growth, driven by technological advancements, increased demand for minimally invasive surgeries, and the rising adoption of robotics in healthcare. The market is expected to grow from $11.5 billion in 2024 to $38.7 billion by 2034, at a CAGR of 12.9%.
The most advanced robotic cardiac ablation lab opens at Penn Presbyterian Medical Center.
